BLFS Quote, Financials, Valuation and Earnings

NeuroOne Medical Technologies has a net margin of -1.87% compared to BioLife Solutions's net margin of -163.76%. BioLife Solutions's return on equity of -3.1% beat NeuroOne Medical Technologies's return on equity of -281.01%.

BioLife Solutions has a consensus price target of $31.22, signalling upside risk potential of 43.35%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of $1.45 which suggests that it could grow by 132.78%. Given that NeuroOne Medical Technologies has higher upside potential than BioLife Solutions, analysts believe NeuroOne Medical Technologies is more attractive than BioLife Solutions.

BioLife Solutions has a beta of 2.012, which suggesting that the stock is 101.198% more volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.671%.

BioLife Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions pays -- of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend.

BioLife Solutions quarterly revenues are $23.9M, which are larger than NeuroOne Medical Technologies quarterly revenues of $1.4M. BioLife Solutions's net income of -$448K is higher than NeuroOne Medical Technologies's net income of -$2.3M. Notably, BioLife Solutions's price-to-earnings ratio is -- while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions is 12.75x versus 3.22x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband has a net margin of -1.87% compared to BioLife Solutions's net margin of -211%. BioLife Solutions's return on equity of -3.1% beat Nutriband's return on equity of -69.58%.

BioLife Solutions has a consensus price target of $31.22, signalling upside risk potential of 43.35%. On the other hand Nutriband has an analysts' consensus of $13.00 which suggests that it could grow by 137.23%. Given that Nutriband has higher upside potential than BioLife Solutions, analysts believe Nutriband is more attractive than BioLife Solutions.

BioLife Solutions has a beta of 2.012, which suggesting that the stock is 101.198% more volatile than S&P 500. In comparison Nutriband has a beta of 1.185, suggesting its more volatile than the S&P 500 by 18.545%.

BioLife Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.

BioLife Solutions quarterly revenues are $23.9M, which are larger than Nutriband quarterly revenues of $645.8K. BioLife Solutions's net income of -$448K is higher than Nutriband's net income of -$1.4M. Notably, BioLife Solutions's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions is 12.75x versus 27.17x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

enVVeno Medical has a net margin of -1.87% compared to BioLife Solutions's net margin of --. BioLife Solutions's return on equity of -3.1% beat enVVeno Medical's return on equity of --.

BioLife Solutions has a consensus price target of $31.22, signalling upside risk potential of 43.35%. On the other hand enVVeno Medical has an analysts' consensus of $12.50 which suggests that it could grow by 273.13%. Given that enVVeno Medical has higher upside potential than BioLife Solutions, analysts believe enVVeno Medical is more attractive than BioLife Solutions.

BioLife Solutions has a beta of 2.012, which suggesting that the stock is 101.198% more volatile than S&P 500. In comparison enVVeno Medical has a beta of 0.803, suggesting its less volatile than the S&P 500 by 19.726%.

BioLife Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.

BioLife Solutions quarterly revenues are $23.9M, which are larger than enVVeno Medical quarterly revenues of --. BioLife Solutions's net income of -$448K is higher than enVVeno Medical's net income of -$4.5M. Notably, BioLife Solutions's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions is 12.75x versus 326.81x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.

SINTX Technologies has a net margin of -1.87% compared to BioLife Solutions's net margin of -787.63%. BioLife Solutions's return on equity of -3.1% beat SINTX Technologies's return on equity of -180.99%.

BioLife Solutions has a consensus price target of $31.22, signalling upside risk potential of 43.35%. On the other hand SINTX Technologies has an analysts' consensus of $30.00 which suggests that it could grow by 1015.24%. Given that SINTX Technologies has higher upside potential than BioLife Solutions, analysts believe SINTX Technologies is more attractive than BioLife Solutions.

BioLife Solutions has a beta of 2.012, which suggesting that the stock is 101.198% more volatile than S&P 500. In comparison SINTX Technologies has a beta of 0.821, suggesting its less volatile than the S&P 500 by 17.937%.

BioLife Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.

BioLife Solutions quarterly revenues are $23.9M, which are larger than SINTX Technologies quarterly revenues of $291K. BioLife Solutions's net income of -$448K is higher than SINTX Technologies's net income of -$2.3M. Notably, BioLife Solutions's price-to-earnings ratio is -- while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions is 12.75x versus 2.58x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.